NCT05732935Befejeződött
Fasting ENHANCE Pilot Study
Fasting to Provide Energy Needed to Help Adults in Need of Cognitive Enhancement (FASTING ENHANCE)
Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. jún. 30.
Rövid összefoglaló (regiszter, angolul)
Grounded in the principles of geroscience, the proposed Fasting ENHANCE study will test whether a time restricted eating (TRE) regimen can improve cognitive function and other aspects of successful aging in a safe and sustainable manner in at risk overweight older adults. Specifically, this study will evaluate whether TRE can improve cognitive and physical function, as well as self-reported sleep, mood, and quality of life, in overweight, older adults (age > 65 years) who are at high risk of cognitive decline due to self-reported cognitive difficulties. Eligible participants will be assigned to either a TRE intervention, in which they will be instructed to fast for a target of 16 hours per day, or a successful aging (SA) comparison group for a 24-week period.
- Állapot (regiszter)
- Befejeződött
- Vizsgálattípus
- Beavatkozással járó
- Résztvevők száma
- 45 (tényleges)
- Első benyújtás
- 2023. jan. 11.
- Kezdés
- 2023. márc. 13.
- Elsődleges befejezés
- 2026. máj. 1.
- Fő szponzor
- University of Florida
- Betegségek
- Elhízás, Alzheimer-kór
- NCT-szám
- NCT05732935
Mit vállalsz
- Vizsgálat típusa: Beavatkozással járó
- Bevont résztvevők: 45
- 2023. márc. 13. és az elsődleges befejezés (2026. máj. 1.) között
- 1 helyszín, 1 országban
- Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket
A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.
Ki nem vehet részt
Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.
Korábbi kezelés
- Current use of anabolic medications (i.e., growth hormones or testosterone), antidepressant medications, antipsychotic agents, monoamine oxidase inhibitors, anticholinesterase inhibitors (i.e., Aricept), anticoagulant therapies (aspirin use is permitted), or antibiotics;
- Rheumatoid arthritis, Parkinson's disease or currently on dialysis
- Taking medications that preclude fasting for 16 hours (e.g. must be taken with food at least 12 hours apart)
- Participating in another clinical trial or has received an investigational product within 30 days prior to screening/enrollment
Más betegség
- Failure to provide informed consent;
- Recent History or clinical manifestation of cardiovascular disease, diabetes, cholelithiasis, liver or renal disease, cancer, or progressive, degenerative neurologic disease (e.g., Parkinson's Disease, multiple sclerosis, ALS)
- Significant cognitive impairment, defined as a scores below the cutoff for dementia on TICS-M
- Severe rheumatologic or orthopedic diseases (e.g., awaiting joint replacement, active inflammatory disease);
- Terminal illness with life expectancy less than 12 months, as determined by a physician;
- Other significant co-morbid disease (e.g. renal failure on hemodialysis) or severe psychiatric disorder (e.g. bipolar, schizophrenia);
- History of drug or alcohol abuse (i.e., more than 5 drinks/day for males or more than 4 drinks/day for females);
- History of pulmonary disease, pneumonitis or interstitial lung disease;
- Resting heart rate of >120 beats per minute, systolic blood pressure > 180 mmHg or diastolic blood pressure of > 100 mmHg
- Unstable angina, heart attack or stroke in the past 3 months
- Continuous use of supplemental oxygen to manage a chronic pulmonary condition or heart failure
- Insulin dependent diabetes mellitus
- Any condition that in the opinion of the investigator would impair ability to participate in the trial.
Laborértékek
- Abnormal laboratory markers (e.g., renal or liver abnormalities, elevated potassium levels, or hemoglobin and hematocrit below the lower limit of normal) as determined by study physician.
- Creatinine clearance < 30 ml/minute by estimated Glomerular Filtration Rate (eGFR);
Egyéb
- Excessive alcohol use (>14 drinks per week);
- Planning to permanently leave the area in the next year;
- Current smoker or less than 3 years quit;
- Fasting >12 hours per day
- Actively trying to lose weight by participating in formal weight loss program or significantly restricting calorie intake or weight loss > 5 lbs in the past month
Kiket keres a vizsgálat
- Age ≥ 65 years;
- Body Mass Index (BMI > 25 kg/m2)
- Normal age-, gender-, and education-adjusted performance on TICS-M (Telephone Interview for Cognitive Status)
- Responds yes to questions 1 (memory worse), 2 (word finding difficulties) or 3 (planning/organization difficulties) on the Subjective Cognitive Decline Questionnaire
- Reports onset of cognitive difficulties in past five years
- Reports they believe they are worse than others their age OR they have talked to a clinician about it.
- Provides informed consent and willing to be randomized to either intervention group.
Életkor a regiszterben: 65 év – - · Nem: nők és férfiak · Egészséges önkénteseket is fogad
Helyszínek (1)
Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.
| Helyszín | Város | Ország | Helyszín állapota |
|---|---|---|---|
| Clinical and Translational Research Building - Institute on Aging Suite | Gainesville | Egyesült Államok | Ismeretlen állapot |
Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.